Amgen (AMGN) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 6/9/2026 – Amgen had its price target raised by Morgan Stanley from $332.00 to $340.00. They now have an “equal weight” rating on the stock.
• 6/6/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/5/2026 – Amgen was given a new $389.00 price target by The Goldman Sachs Group, Inc..
• 5/23/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/20/2026 – Amgen had its price target lowered by Argus from $400.00 to $375.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Amgen had its price target lowered by Piper Sandler from $432.00 to $427.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Amgen had its price target lowered by Daiwa Securities Group Inc. from $410.00 to $390.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Amgen was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 5/5/2026 – Amgen had its “hold” rating reaffirmed by Erste Group Bank AG.
• 5/4/2026 – Amgen had its price target lowered by Guggenheim from $351.00 to $340.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Amgen was given a new $332.00 price target by Morgan Stanley.
• 5/1/2026 – Amgen had its price target raised by Truist Financial Corporation from $325.00 to $327.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $415.00 to $425.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/25/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/20/2026 – Amgen is now covered by Canaccord Genuity Group Inc.. They set a “hold” rating and a $366.00 price target on the stock.
• 4/13/2026 – Amgen had its price target raised by UBS Group AG from $390.00 to $400.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.